Health Related Quality of Life in Patients with Type 2 Diabetes Mellitus in Iran : A National Survey by Javanbakht, Mehdi et al.
Health Related Quality of Life in Patients with Type 2
Diabetes Mellitus in Iran: A National Survey
Mehdi Javanbakht1,2*, Farid Abolhasani3, Atefeh Mashayekhi1, Hamid R. Baradaran4, Younes Jahangiri
noudeh5
1Health Care Management and Economic Research Center, School of Health Care Management, Tehran University of Medical Sciences, Tehran, Iran, 2 School of Health
Care Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran, 3 Endocrinology and Me`olism Research Institute, Tehran University of
Medical Sciences, Tehran, Iran, 4 Endocrine Research Center (Firouzgar), Institute of Endocrinology and Metabolism, Tehran University of Medical Sciences, Tehran, Iran,
5 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Introduction: The aim of this study was to measure health-related quality of life (HRQoL) in Iranian people with Type 2
Diabetes Mellitus using two different measures and examines which socio-demographic and diabetes-related characteristics
are associated with better quality of life based on a nationally distributed sample.
Methods: A multi-stage cluster sampling method was used to select 3472 subjects as a part of Iranian surveillance of risk
factors of non-communicable disease (ISRFNCD). EuroQol-5 Dimensions questionnaire (EQ-5D) and Visual Analog Scale
(VAS) were employed to measure HRQoL. Binary logistic and Tobit regression models were used to investigate factors
associated with EQ-5D results.
Results: The mean age of subjects was 59.4 years (SD= 11.7), 61.3% were female and had 8.08 years (SD = 6.7) known
duration of diabetes. The patients reported ‘‘some or extreme problems’’ most frequently in Pain/Discomfort (69.3%) and
Anxiety/Depression (56.6%) dimensions of EQ-5D. The mean EQ-5D and VAS score were 0.70 (95% CI 0.69–0.71) and 56.8
(95% CI 56.15–57.5) respectively. Female gender, lower education, unemployment, long duration of diabetes, diabetes-
related hospitalization in past years and having nephropathy and lower extremity lesions were associated with higher
probabilities of reporting ‘‘some or extreme problems’’ in most dimensions of EQ-5D in binary logistic regression models.
The same factors in addition to retinopathy were significantly associated with lower levels of HRQoL in Tobit regression
analysis too.
Conclusions: The study findings indicate that patients with diabetes in Iran suffer from relatively poor HRQoL. Therefore
much more attention should be paid to main determinants of HRQoL to identify and implement appropriate policies for
achieving better management of diabetes and ultimately improving the quality of life of diabetic patients in this region.
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Introduction
The risk of diabetes continues to increase worldwide due to
population growth, aging, urbanization and increasing prevalence
of physical inactivity and obesity [1]. The most recent data from
International Diabetes Federation (IDF) indicate that the Middle
East and North Africa (MENA) region has the highest rate of
diabetes prevalence in the world. In this region about 12.5% of
adults aged 20–79 years or 32.8 million people had diabetes in
2011 year and this number is expected to double in less than
20 years [2].
Type 2 diabetes mellitus (T2DM) is a complex and a serious
chronic disease that impose a significant burden on patients and
society in a term of morbidity and premature mortality[3,4]. In the
long term, diabetic patients have to face many complications. In
addition to diabetes-related complications, episodes and fear of
hypoglycemia and change in life style are the main cause of health-
related quality of life (HRQoL) diminution [5].
Due to limited resource in health systems in worldwide demand
for economic evaluations of health care programs, especially
pharmaceuticals, is steadily increasing. One of the most important
issues in this field is how to measure, value and incorporate
changes in quality of life into the economic evaluation [6].
Moreover the importance of HRQoL in clinical research has been
extensively discussed over recent years and there is an increasing
recognition among clinicians and researchers that the impact of
chronic illnesses and their treatments must be assessed in terms of
their HRQoL in addition to more traditional measures of clinical
outcomes – morbidity and mortality[7–9].
Heretofore a limited number of studies have been conducted in
the Middle East to document the HRQoL of patients with T2DM
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[10–13]. Therefore the aim of this study was to measure HRQoL
in Iranian patients with T2DM and examine which patient’s socio-
demographic and diabetes-related clinical characteristics are
associated with better quality of life based on a nationally
distributed sample.
Methods
Study Subjects and Sampling Design
This study conducted as a part of Iranian surveillance of risk
factors of non-communicable disease system (ISRFNCD) that
provided the demographic, anthropometric and biochemical
characteristics on nationwide samples of Iranian adults. A multi-
stage cluster sampling method was used to select 3918 patients
with T2DM for study. Sampling frame was defined in 50 clusters
for every 30 provinces. There is no distinction between rural and
urban areas in samples, so that the samples were selected
proportional to urban- rural population. All participants were
visited by trained interviewers and were invited to participate by
receiving informed consent. Subjects were eligible for the study if
at the first they met WHO criteria (fasting plasma glucose
$7.0 mmol/l (126 g/dl) or with a glucose tolerance test, two
hours after the oral dose a plasma glucose $11.1 mmol/l
(200 mg/dl)). Second were age 16 years or older and third were
willing and able to give written informed consent and complete the
questionnaire interview. Written informed consent also was
obtained from guardian of individuals who were under 18 years
old. Finally 3472 patients that completed two assigned question-
naires, included in the final analysis. The study has been approved
by the ethics committee of the Iran’s Ministry of Health (MOH)."
Measures
Data were collected using two questionnaires, a socio-demo-
graphic and clinical history questionnaire and a validated Farsi
version of HRQoL questionnaire. First one recorded details of age,
gender, education level, Living condition, employment and
marital status, disease duration, mode of treatment and related
comorbidity. To determine the health status, the EQ-5D 3L
questionnaire was used. It includes 5 questions, each assessing one
of 5 dimensions of the HRQoL (Mobility (MO), Self-Care (SC),
Usual Activities (UA), Pain/Discomfort (P/D) and Anxiety/
Depression (A/D)). Each dimension has to be answered on a
three–level scale (no problems, some or moderate problems, and
extreme problems). The scales are given a score from 1 (no
problem) to 3 (extreme problem) in each question; and finally the
score digits are placed together to yield a 5-digit code for HRQoL
of each patient. In this method, 243 (3 in power of 5) different
codes are probable. EuroQol Group members have carried out
researches mainly focused upon statistical modeling methods
aimed at generating numerical values for each of 243 probable
health states defined by EQ-5D. Value sets are commonly
produced by valuing a selection of EQ-5D states and to
extrapolate over the full set of states. In this study due to the
absence of a locally appropriate set of values, as suggested by
EuroQol Group the EQ-5D score was calculated using the UK
VAS value set [14].The EQ-5D also contains a visual analog scale
(VAS), measuring the subjects’ perspectives of their quality of life
level on a 100- point scale. The best state carries a score of 100
and the worst state a score of 0. This information can be used as a
quantitative measure of health outcome as judged by the
individual respondents. If patients had ability to answer the
questions, they filled it personally; otherwise a trained interviewer
collected the necessary data through face-to-face interviews with
respondents.
Statistical Analysis
The continuous variables were expressed as mean 6 standard
deviation and categorical variables as absolute numbers and
percentages. Chi-square test was performed for the five dimensions
of health status. As there were significant differences in EQ-5D
and VAS scores according to age, sex, education level, employ-
ment status, diabetes duration and some comorbidity the mean
values were adjusted by these parameters using analysis of
covariance (ANCOVA). For all 5 dimensions level 2 and 3 on
the EQ-5D dimensions were merged and thus dichotomized to
‘‘no problem’’ or ‘‘some or extreme problem’’. We used logistic
regression to obtain odds ratios (ORs) and 95% confidence
intervals (95% CIs) for determinants of EQ-5D dimensions after
adjustment for covariates. Confidence intervals were calculated
using the bias-corrected accelerated (BCA) percentile bootstrap-
ping method. Finally, a Tobit regression model was constructed to
find factors that affected the HRQoL of the patients, using EQ-5D
score as a dependent variable. The Tobit regression model is
suitable for two reasons. First, the distribution of the dependent
variable is skewed and censored at 20.053 and 1. Second, a
considerable number of observations were at the upper limit of 1
(21.9%). All analyses were performed using STATA/SE 10.0 for
Windows and SPSS Version 15.0.
Results
The patients’ characteristics have been described in details in
table 1. The mean age of respondents was 59.4 years (SD = 11.7),
61.3% were female and the mean duration of diabetes was
8.08 years (SD = 6.7). About 80.8% was married, 82.3% had less
than 6 grades education and 82.1% used combination therapy to
control diabetes. Of the 3472 investigated patients, 32.6%, 21.6%,
40.4% and 10.7% reported that they had cardiovascular
comorbidity, nephropathy, retinopathy and lower extremity
lesions respectively.
Dimensions of EQ-5D
In total 30%, 24.6%, 32.9%, 69.3% and 56.6% of the patients
reported ‘‘some or extreme problems’’ in MO, SC, UA, P/D and
A/D dimensions of EQ-5D respectively (Table 2). Examination of
health status in both sex revealed that, the frequency of ‘‘some or
extreme problems’’ were significantly higher in females for all
dimensions (P,0.05). Patients in the 50 years had ‘‘some or
extreme problems’’ and older group, those who divorced or lost
their couple and those who had less than 6 grades education
reported higher rate of ‘‘some or extreme problems’’ than patients
in other groups in all dimensions. Same as subjects who were
employed, the frequency of ‘‘some or extreme problems’’ for all
dimensions were lower in patients who lived in region with
populations 500000–1000000, compared to patients in other
groups (P,0.05). As expected patients who had diabetes for longer
time (5–10 and more than 10 years) reported significantly higher
rate of had ‘‘some or extreme problems’’ in all dimensions except
A/D. The frequency of ‘‘some or extreme problem’’ responses was
significantly higher in subjects who had diabetes related hospital-
ization in past year (P,0.05). For the relationship between the
presence of diabetic complications and health status, the frequency
of ‘‘some or extreme problems’’ responses was significantly higher
for all dimensions in patients with neuropathy and cardiovascular
comorbidity and lower extremity lesions. Nevertheless, the
presence of nephropathy and retinopathy comorbidity did not
show a statistically significant relationship for the UA and MO and
P/D dimensions respectively.
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EQ-5D and VAS Scores
The mean EQ-5D and VAS score were 0.70 (95% CI 0.69–
0.71) and 56.8 (95% CI 56.15–57.5) respectively (table 3). The
EQ-5D and VAS score were lower in females compared to male
(0.67 vs. 0.74 for EQ-5D and 55.1 vs. 57.9 for VAS score). The
patients who were older than 70 years, those who were divorced
and loosed couple and where unemployed and those who had less
than 6 grade education reported significantly lower EQ-5D and
VAS scores compared to other groups. There wasn’t Significant
differences in EQ-5D score by treatment modality and living
condition. We found that the patients who had diabetes related
hospitalization in past year reported significantly lower EQ-5D
and VAS scores (0.61 vs. 0.72 and 50.4 vs. 57.9). Those who had
diabetes for longer time were reported lower EQ-5D and VAS
scores. Finally those who had diabetes comorbidities reported
significantly lower EQ-5D scores. The health status reported by
EQ-5D scores was similar to that reported by VAS score, and
there was a statistical relationship between EQ-5D score and VAS
score (Spearman correlation test, P= 0.618; P,0.01).
Regression models
Multivariate logistic regression models for each of the five
dimensions of EQ-5D are shown in Table 4. Female reported
more ‘‘some or extreme problems’’ with all dimensions of EQ-5D
(MO; OR = 2.24, SC; OR = 2.61, UA; OR = 3.04, P/D; OR
= 2.29; A/D; OR = 1.69). As indicated in table 4, the results
showed that sex, education, employment status, diabetes related
hospitalization in past year, duration of diabetes; nephropathy
comorbidity and lower extremity lesions were significantly
associated with reporting problems in the most dimensions of
EQ-5D. Nonetheless marital status, living condition, treatment
regime and retinopathy and cardiovascular comorbidity did not
show significant results although the findings were in the expected
direction.
The results of Tobit regression model showed that the odds ratio
of EQ-5D score compared to reference group was as follow; in
female (0.85 95% CI 0.81–0.89), among who were older than
70 years (0.85 CI 0.73–1), in patients who had .12 grades
education (1.17 CI 1.1–1.25), for unemployed subjects (0.89 CI
0.86–0.92), for those who had diabetes related hospitalization in
past years (1.13 CI 1.1–1.16), among those who lived in Small
town (1.03 CI 1–1.06), for those who had diabetes more than
10 years (0.89 CI 0.86–0.92), in patients with nephropathy
comorbidity (0.93 CI 0.91–0.96) and for those with lower
extremity lesions were (0. 9 CI 0.87–0.94) (table 5).
Discussion
To our best knowledge it seems that this is the first population-
based study to investigate HRQoL of patients with T2DM in
MENA region; where that has highest rate of diabetes prevalence
in world. We measured the health status by EQ-5D and calculated
the EQ-5D score, to investigate the relationship between EQ-5D
and VAS scores and patient characteristics that are associated with
HRQoL. Synthesis of literature indicated that the EQ-5D has
been used to measure HRQoL of diabetic patients in different
countries [15–19]. The EQ-5D has been used in the UK
Prospective Diabetes Study (UKPDS) to determine the effects of
therapy, complications, and hypoglycemic episodes on HRQoL in
patients with T2DM too [20]. We used EQ-5D for two reasons,
first using the EQ-5D instrument able us to transform the utility
scores into quality-adjusted life years for use in economic
evaluations of new therapies. Second the shorter completion time
compared with other generic instruments.
Table 1. Characteristics of the patients.
Variables Number (3472) (%)
Sex
Male 1344 38.7
Female 2128 61.3
Age group
#30 years 44 1.3
30–40 years 145 4.2
40–50 years 599 17.3
50–60 years 1042 30.0
60–70 years 1060 30.5
.70 years 582 16.8
Marital status
Single 32 0.9
Married 2805 80.8
Divorced and loosed couple 635 18.3
Education
#6 grade 2857 82.3
6–12 grade 474 13.7
.12 grade 141 4.1
Employment
Employed 690 19.9
Housewives+ students 1911 55
Unemployed 871 25.1
Living area
Megacity (.1000000 population) 597 17.2
City (500000–1000000 population) 406 11.7
Small town (,500000) 2469 71.1
Treatment
No treatment 427 12.3
Diet and exercise 195 5.6
Combination therapy (Medication +
Diet and exercise)
2850 82.1
Diabetes related hospitalization in past year
Yes 767 22.1
No 2705 77.9
Diabetes duration
,5 years 1384 39.9
5–10 years 1428 41.1
.10 years 660 19
Cardiovascular comorbidity
No 2246 67.4
Yes 1226 32.6
Nephropathy comorbidity
No 2722 78.4
Yes 750 21.6
Retinopathy comorbidity
No 2069 59.6
Yes 1403 40.4
Lower extremity lesions
No 3100 89.3
Yes 372 10.7
doi:10.1371/journal.pone.0044526.t001
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Table 2. Results of EQ-5D dimensions.
Variable Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
Sex
Male 23.1 ,0.001* 17.0 ,0.001* 24.3 ,0.001* 60.0 ,0.001* 48.1 ,0.001*
Female 34.3 29.4 38.3 75.2 62.0
Age group
#30 years 6.8 ,0.001* 6.8 ,0.001* 4.5 ,0.001* 36.4 0.001* 40.9 0.001*
30–40 years 8.3 4.8 11.0 50.3 57.2
40–50 years 15.4 10.4 17.7 55.6 51.3
50–60 years 23.1 17.2 25.6 68.1 55.1
60–70 years 33.9 28.1 37.3 74.4 57.5
.70 years 57.2 52.4 61.2 83.3 64.3
Marital status
Single 12.5 ,0.001* 9.4 ,0.001* 15.6 ,0.001* 37.5 ,0.001* 31.3 ,0.001*
Married 26.5 21.0 29.2 66.7 54.8
Divorced and loosed
couple
46.3 41.4 50.1 82.5 66.1
Education
#6 years 33.8 ,0.001* 28.2 ,0.001* 37.4 ,0.001* 73.3 ,0.001* 58.5 ,0.001*
6–12 years 13.7 9.3 13.3 52.5 49.8
.12 years 6.4 3.5 7.8 44.7 42.6
Employment
Employed 12.9 ,0.001* 7.1 ,0.001* 14.2 ,0.001* 54.3 ,0.001* 42.2 ,0.001*
Housewives + Students 32.3 27.4 36.0 74.1 61.0
Unemployed 38.3 32.4 40.9 70.5 58.6
Living area
Megacity (.1000000
population)
34.3 ,0.001* 30.7 ,0.001* 38.7 ,0.001* 73.2 ,0.001* 59.3 ,0.001*
City (500000–1000000
population)
19.2 13.3 21.9 58.4 44.3
Small town (, 500000) 30.7 25.0 33.3 70.1 58.0
Treatment
No treatment 21.2 ,0.001* 18.2 ,0.001* 21.2 ,0.001* 57.6 ,0.001* 47.0 0.001*
Diet and exercise 18.5 13.8 20.5 58.5 47.2
Combination therapy
(Medication + Diet and
exercise)
32.2 26.3 35.2 72.1 58.7
Diabetes duration
,5 years 23.8 ,0.001* 18.8 ,0.001* 25.7 ,0.001* 61.8 ,0.001* 47.9 ,0.001*
5–10 years 32.1 26.4 35.6 71.8 58.2
.10 years 39.2 33.5 43.3 80.5 61.3
Diabetes related hospitalization in past year
Yes 46.4 ,0.001* 41.5 ,0.001* 50.7 ,0.001* 82.4 ,0.001* 69.9 ,0.001*
No 25.3 19.8 27.8 65.6 52.9
Cardiovascular Comorbidity
No 27.6 ,0.001* 22.0 ,0.001* 29.9 ,0.001* 68.4 ,0.001* 54.9 ,0.001*
Yes 38.5 32.3 42.3 76.4 63.6
Nephropathy Comorbidity
No 32.6 ,0.001* 24.1 0.002* 34.5 0.219 67.2 ,0.001* 55.5 ,0.001*
Yes 25.6 30.0 31.9 84.7 65.8
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Table 2. Cont.
Variable Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
% of any
problems P-value
Retinopathy Comorbidity
No 30.0 0.089 24.0 0.036* 31.9 0.003* 70.4 0.370 55.6 0.003*
Yes 32.8 27.3 37.0 71.9 60.9
Lower extremity lesions
No 29.3 ,0.001* 23.9 ,0.001* 32.5 ,0.001* 69.7 ,0.001* 57.0 0.012*
Yes 46.7 37.3 46.1 81.9 64.2
Total 30.0 24.6 32.9 69.3 56.6
Notes: P-value: chi-square test; No marks: not significant.
doi:10.1371/journal.pone.0044526.t002
Table 3. EQ-5D and Visual Analog Scale (VAS) scores.
Variable EQ-5D Score VAS
Mean 95% CI P- value Mean 95% CI P- value
Sex
Female 0.67 0.66 0.68 ,0.001* 55.16 54.27 56.06 0.001*
Male 0.74 0.72 0.75 57.90 56.72 59.07
Age group
#30 years 0.72 0.62 0.82 ,0.001* 57.95 50.69 65.21 ,0.001*
30–40 years 0.71 0.67 0.76 59.23 55.70 62.77
40–50 years 0.73 0.71 0.75 59.21 57.46 60.96
50–60 years 0.73 0.72 0.75 58.95 57.72 60.18
60–70 years 0.69 0.68 0.71 55.35 54.14 56.57
.70 years 0.60 0.58 0.62 49.31 47.58 51.04
Marital status
Single 0.69 0.59 0.80 ,0.001* 52.14 44.13 60.15 0.001*
Married 0.71 0.70 0.72 56.90 56.14 57.66
Divorced and loosed couple 0.65 0.63 0.67 53.39 51.69 55.09
Education
#6 years 0.69 0.67 0.69 ,0.001* 54.96 54.21 55.72 ,0.001*
6–12 years 0.74 0.71 0.76 61.49 59.52 63.46
.12 years 0.79 0.74 0.83 64.22 60.77 67.67
Employment
Employed 0.69 0.66 0.72 ,0.001* 56.86 54.66 59.07 ,0.001*
Housewives + students 0.74 0.72 0.76 58.08 56.67 59.49
Unemployed 0.60 0.58 0.63 51.63 49.81 53.46
Living area
Megacity (.1000000 population) 0.678 .657 .700 0.146 54.56 52.93 56.20 0.01*
City (500000–1000000 population) 0.714 .678 .750 59.20 56.47 61.93
Small town (,500000) 0.699 .688 .709 56.33 55.56 57.10
Treatment
No treatment 0.68 0.66 0.70 0.106 56.21 51.58 60.85 0.159
Diet and exercise 0.71 0.68 0.75 58.79 56.06 61.52
Combination therapy (Medication + Diet
and exercise)
0.70 0.69 0.71 56.02 55.31 56.72
Diabetes duration
,5 years 0.74 0.72 0.75 ,0.001* 58.05 56.91 59.18 ,0.001*
5–10 years 0.69 0.68 0.70 56.18 55.16 57.20
.10 years 0.64 0.62 0.66 53.06 51.57 54.55
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Table 3. Cont.
Variable EQ-5D Score VAS
Mean 95% CI P- value Mean 95% CI P- value
Diabetes related hospitalization in past year
Yes 0.61 0.59 0.63 ,0.001* 50.48 49.08 51.88 ,0.001*
No 0.72 0.71 0.73 57.96 57.19 58.73
Cardiovascular comorbidity
No 0.70 0.69 0.71 0.049* 56.39 55.55 57.22 0.449
Yes 0.68 0.67 0.70 55.80 54.58 57.03
Nephropathy comorbidity
No 0.66 0.64 0.68 ,0.001* 56.85 56.09 57.62 ,0.001*
Yes 0.71 0.70 0.72 53.86 52.41 55.31
Retinopathy comorbidity
No 0.69 0.68 0.70 0.042* 56.12 55.23 57.00 0.780
Yes 0.71 0.69 0.72 56.32 55.24 57.39
Lower extremity lesions
No 0.71 0.70 0.71 ,0.001* 56.26 55.55 56.97 0.604
Yes 0.62 0.59 0.65 55.68 53.61 57.75
Total 0.70 0.69 0.71 56.84 56.15 57.50
Notes: EQ-5D and VAS scores: mean values adjusted by sex, age, education, marriage and employment status, diabetes duration and comorbidities; P-value: ANCOVA.
No marks: not significant. VAS: visual analog scale.
doi:10.1371/journal.pone.0044526.t003
Table 4. Results of multivariate logistic regression models.
Variable Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
OR P-value OR P-value OR P-value OR P-value OR P-value
Sex
Male 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Female 2.24 ,0.001 * 2.61 ,0.001 * 3.04 ,0.001 * 2.29 ,0.001 * 1.69 0.002*
Age group
,= 30 years 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
30–40 years 0.82 0.806 0.36 0.238 2.52 0.322 1.38 0.546 0.76 0.619
40–50 years 1.42 0.646 0.68 0.627 3.73 0.151 1.31 0.606 0.49 0.170
50–60 years 1.68 0.492 0.86 0.852 4.40 0.104 1.72 0.296 0.47 0.157
60–70 years 2.45 0.236 1.47 0.624 6.53 0.04* 2.14 0.144 0.45 0.133
.70 years 5.87 0.020* 3.66 0.102 15.48 0.003* 3.28 0.02 0.52 0.221
Marital status
Single 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Married 0.65 0.541 0.87 0.860 0.32 0.105 1.46 0.493 3.65 0.024
Divorced and loosed couple 0.79 0.743 1.01 0.992 0.36 0.146 1.77 0.314 4.40 0.011*
Education
,6 years 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
6–12 years 0.49 ,0.001* 0.47 ,0.001 * 0.37 ,0.001* 0.62 ,0.001* 0.87 0.263
.12 years 0.20 ,0.00* 0.15 ,0.001 0.21 ,0.001* 0.51 ,0.001* 0.76 0.185
Employment
Employed 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Housewives + students 1.22 0.372 1.52 0.092 0.93 0.749 0.92 0.696 1.22 0.283
Unemployed 2.44 ,0.001* 3.11 ,0.001* 2.26 ,0.001* 1.38 0.014 1.66 ,0.001*
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We showed that the patients reported ‘‘some or extreme
problems’’ in a range of 24.6%–69.3% with highest rate for P/D
and A/D dimensions. Review of literature indicated that problems
in the P/D and A/D dimensions were most frequently reported
[17,21]. Although Sakamaki and his colleague showed that
diabetic patients had reported more problem with Mo and P/D
dimensions[19].
We concluded that mean EQ-5D score in Iranian patients with
T2DM was 0.70 while investigation of studies that used same
instruments in Japanese, Canadian, Korean and Norwegian
patients were 0.862, 0.75, 0.9 and 0.85 respectively[15,17,19,22].
Many socioeconomic and healthcare system related factors
influence HRQoL of diabetic patients; therefore comparison of
results should be interpreted with caution. Some of these
differences could be explained by difference in main characteristics
of studied subjects such as; mean age, duration of diabetes and
comorbidities. Moreover since diabetes produces few symptoms
and is initially not life threatening, many people, particularly in
developing countries, often do not seek medical attention until
other incapacitating symptoms or complications develop [23,24].
Delay in diagnosis can directly increase complications and then
lead to higher diminution of patient’s HRQoL.
We have concluded that mean EQ-5D score was lower in
female compared to male. This finding is in accordance with other
studies of similar patients [15,18,19,25,26]. Better social life and
physical activity of men in developing countries like Iran might
contribute to higher level of satisfaction; also women tend to be
more expressive and thus are more likely to complain about a poor
quality of life. Moreover studies have shown that men were more
confident of their ability to control diabetes and reported a higher
quality of life and were less likely to get depression or anxiety
compared to women [27]. Our results showed that increased age
was associated with lower HRQoL. Other studies have reported
same finding [15,26,28,29]. Surprisingly, in contrast to these
studies and our findings, Daria and his colleague showed that
increased age was associated with better HRQoL [22]. Our results
showed that being female, less educated and unemployed, having
diabetes related hospitalization in past years, living in bigger cities,
having diabetes for longer time, having nephropathy and
retinopathy comorbidity and lower extremity lesions were
Table 4. Cont.
Variable Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
OR P-value OR P-value OR P-value OR P-value OR P-value
Treatment
No treatment 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Diet and exercise 0.71 0.361 0.61 0.230 0.84 0.652 1.04 0.897 0.97 0.908
Medication 1.01 0.972 0.86 0.678 1.15 0.667 1.35 .277 1.26 0.375
Living area
Megacity
(.1000000 population)
1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
City
(500000–1000000 population)
0.94 0.771 0.61 0.049* 0.84 0.390 0.80 0.261 0.68 .032*
Small town (, 500000) 0.91 0.384 0.75 0.013* 0.84 0.104 0.80 0.060 0.84 .084
Diabetes duration
,5 years 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
5–10 years 1.27 0.02* 1.26 0.035* 1.33 0.004* 1.38 0.001* 1.38 ,0.001*
.10 years 1.68 ,0.001* 1.74 ,0.001 1.81 ,0.001* 2.10 ,0.001* 1.50 ,0.001*
Diabetes related hospitalization in past year
Yes 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
No 0.51 ,0.001* 0.45 ,0.001* 0.48 ,0.001* 0.47 ,0.001* 0.57 ,0.001*
Cardiovascular comorbidity
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.16 0.121 1.19 0.102 1.22 0.042* 1.12 0.260 1.14 0.139
Nephropathy comorbidity
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.58 ,0.001* 1.28 0.026* 0.76 0.009* 2.80 ,0.001* 1.53 ,0.001*
Retinopathy comorbidity
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.86 0.101 0.86 0.138 0.96 0.683 0.81 0.025* 1.05 0.545
Lower extremity lesions
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 2.02 ,0.001* 1.73 ,0.001* 1.54 .001* 1.64 0.002* 1.15 0.284
Notes: OR: Odds Ratio; Ref: reference group, No marks: not significant.
doi:10.1371/journal.pone.0044526.t004
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significantly associated with lower EQ-5D scores. These results are
in accordance with the findings reported by Rubin and his
colleague, who systematically analyzed all recent literature on
diabetes and quality of life [30]. Moreover Redekop et al found
that older age, female sex, insulin therapy, presence of complica-
tions, and obesity were associated with a lower HRQoL [18].
Education level had a linear relationship with quality of life. As
the educational level increased the quality of life increased. This
could be due to they will have a better understanding of the
disease, its effect on them, and will avail themselves the best
treatment they can afford. Duration of disease has shown a
variable that affect HRQoL negatively. In two Finnish studies
duration was associated with reduced HRQoL, particularly
physical functioning [31,32]. Similarly Arghese et al and Saito
his colleague in two different studies showed that as duration of the
disease increases, the health of the patient will gradually worsen
depending on his control of diabetes [33,34]. Conversely number
of studies conducted in different countries found no association
between disease duration and HRQoL that was measured by
generic and specific instruments [16,18,35,36].
Our results showed that there was no detectable difference in
EQ-5D score among patients in different treatment group. Speight
and his colleague concluded that the EQ-5D may capture
differences due to diabetes related complications it will not
necessarily be able to capture differences across treatment
regimens. This is because the extent to which a given treatment
is considered flexible or convenient will not affect quality of health
but may affect aspects of quality of life, such as social or working
life [37]. Similarly other study in Japan found same results and
suggest that EQ-5D is less sensitive than disease-specific scales to
treatment modality and should be used in combination with the
disease-specific scale for clinical evaluations [19].
We used ordinal logistic regression analysis to create five
models, one for each dimension, to determine which patient
characteristics were associated with reporting problems in these
dimensions. Although the composition varied somewhat between
models, several patient characteristics appeared in at least three of
the five models. Solli and his colleague concluded that age,
impaired vision, stroke, neuropathy, body mass index, sex,
limitations at work, number of hospital admissions during the
previous 6 months, fear of hypoglycemia and receiving help from
others were statistically significant determinants of reporting
problem in different dimensions of EQ-5D [17].
The results of Tobit regression model showed that female sex,
less educated and unemployed status, having diabetes related
hospitalization in past years, living in bigger cities, having diabetes
for longer time, having nephropathy and retinopathy comorbidity
and lower extremity lesions were significantly associated with
lower EQ-5D scores. Solli and his colleague showed that stroke,
neuropathy, disability pension, receiving help from others, fear of
hypoglycaemia and limitations at work were significantly associ-
ated with EQ-5D score, where a linear regression model was used
[17].
There are several limitations of our study that merit consider-
ation in interpreting results. First, although diabetes complications
were closely related to individual HRQoL level [15,17,18], we did
not assess all diabetic complications effect on HRQoL because
ISRFNCD is not a survey only for diabetes and does not provide
all data related to diabetes complications. We also lacked
information on potentially useful clinical variables. Furthermore
our study was performed at one point in time, and fluctuations are
likely to occur if HRQoL measured at multiple points in time.
Since this is a cross-sectional study, the observed associations are
not necessarily causal.
Table 5. Results of Tobit regression model.
Indicator EQ-5D Score
Odds Ratio 95% CI P- value
Sex
Male 1 (Ref.)
Female 0.85 0.81 0.89 ,0.001*
Age group
,= 30 years 1 (Ref.)
30–40 years 0.96 0.82 1.13 0.632
40–50 years 1.00 0.86 1.16 0.961
50–60 years 0.99 0.85 1.15 0.884
60–70 years 0.95 0.82 1.10 0.500
.70 years 0.85 0.73 1.00 0.044*
Marital Status
Single 1 (Ref.)
Married 0.92 0.78 1.08 0.295
Divorced and loosed couple 0.88 0.74 1.03 0.117
Education
,6 years 1 (Ref.)
6–12 years 1.09 1.05 1.13 ,0.001*
.12 years 1.17 1.10 1.25 ,0.001*
Employment
Employed 1 (Ref.)
Housewives+ students 1.03 0.98 1.09 0.266
Unemployed 0.89 0.86 0.92 ,0.001*
Treatment
No treatment 1 (Ref.)
Diet and exercise 1.07 0.98 1.16 0.161
Medication 1.02 0.94 1.10 0.613
Living area
Megacity (.1000000 population) 1 (Ref.)
City (500000–1000000 population) 1.06 1.00 1.11 0.043*
Small town (,500000) 1.03 1.00 1.06 0.039*
Diabetes duration
,5 years 1 (Ref.)
5–10 years 0.94 0.92 0.97 ,0.001*
.10 years 0.89 0.86 0.92 ,0.001*
Diabetes related hospitalization in past year
Yes 1 (Ref.)
No 1.13 1.10 1.16 ,0.001*
Cardiovascular comorbidity
No 1 (Ref.)
Yes 0.98 0.95 1.00 0.052
Nephropathy comorbidity
No 1 (Ref.)
Yes 0.93 0.91 0.96 ,0.001*
Retinopathy comorbidity
No 1 (Ref.)
Yes 1.03 1.00 1.05 0.029*
Lower extremity lesions
No 1 (Ref.)
Yes 0.90 0.87 0.94 ,0.001*
Notes: No marks: not significant.
doi:10.1371/journal.pone.0044526.t005
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The study findings indicate that patients with diabetes in Iran
suffer from relatively poor HRQoL. Therefore much more
attention should be paid to main determinants of HRQoL to
identify and implement appropriate policies for achieving better
management of diabetes and ultimately improving the quality of
life of diabetic patients in this region. Because of the relationships
found in this study as well as in other studies, it is reasonable to
conclude that any efforts to avoid or postpone obesity, inactivity,
smoking, and development of complications will enhance HRQoL
and thereby improve healthy life expectancy.
Acknowledgments
The authors would like to thank kindly all participants in the study.
Author Contributions
Conceived and designed the experiments: MJ FA. Performed the
experiments: MJ FA AM HRB. Analyzed the data: MJ AM HRB YJn.
Contributed reagents/materials/analysis tools: MJ FA AM. Wrote the
paper: MJ AM HRB.
References
1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of
diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:
1047–1053.
2. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF Diabetes Atlas: Global
estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research
and Clinical Practice 10: 311–321.
3. Roglic G, Unwin N (2011) Mortality Attributable to Diabetes : Estimates for the
Year 2010. IDF Diabetes Atlas fourth edition.
4. Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME,
et al. (2011) Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. PLoS
ONE 6: e26864.
5. Akinci F, Yildirim A, Go¨zu¨ H, Sargın H, Orbay E, et al. (2008) Assessment of
health-related quality of life (HRQoL) of patients with type 2 diabetes in Turkey.
Diabetes Research and Clinical Practice 79: 117–123.
6. Blumenschein K, Johannesson M (1996) Incorporating quality of life changes
into economic evaluations of health care: an overview. Health Policy 36: 155–
166.
7. Hahl J, Hamalainen H, Sintonen H, Simell T, Arinen S, et al. (2002) Health-
related quality of life in type 1 diabetes without or with symptoms of long-term
complications. Quality of Life Research 11: 427–436.
8. Ardito SQ, Bestetti RB, Cardinalli-Neto A, Otaviano AP, Nogueira PR (2011)
Chronic renal impairment in patients with Chagas cardiomyopathy with chronic
systolic heart failure: Prevalence and prognostic significance. International
Journal of Cardiology 152: 133–134.
9. Joshi V, Mooppil N, Lim J (2010) Validation of the Kidney Disease Quality of
Life-Short Form: a cross-sectional study of a dialysis-targeted health measure in
Singapore. BMC Nephrology 11: 36.
10. Ucan O, Ovayolu N (2010) Relationship between diabetes mellitus, hyperten-
sion and obesity, and health-related quality of life in Gaziantep, a central south-
eastern city in Turkey. Journal of Clinical Nursing 19: 2511–2519.
11. Sanjari M, Safari S, Shokoohi M, Safizadeh H, Rashidinezhad H, et al. (2011) A
Cross-Sectional Study in Kerman, Iran, on the Effect of Diabetic Foot Ulcer on
Health-Related Quality of Life. International Journal of Lower Extremity
Wounds 10: 200–206.
12. Taghdisi MH, Borhani M, Solhi M, Afkari ME, Hosseini F (2012) The effect of
an education program utilising PRECEDE model on the Quality of Life in
patients with type 2 diabetes. Health Education Journal 71: 229–238.
13. AlMaskari MY, AlShookri AO, AlAdawi SH, Lin KG (2012) Assessment of
quality of life in patients with type 2 diabetes mellitus in Oman. Saudi Medical
Journal 32: 1285–1290.
14. Szende A, Oppe M, Devlin N (2007) EQ-5D Value Sets: Inventory,
Comparative Review and User Guide. Springer: 1–95.
15. Lee WJ, Song KH, Noh JH, Choi YJ, Jo MW (2012) Health-Related Quality of
Life Using the EuroQol 5D Questionnaire in Korean Patients with Type 2
Diabetes. Journal of Korean Medical Science 27: 255–260.
16. Choi YJ, Lee MS, An SY, Kim TH, Han SJ, et al. (2011) The Relationship
between Diabetes Mellitus and Health-Related Quality of Life in Korean Adults:
The Fourth Korea National Health and Nutrition Examination Survey (2007–
2009). Diabetes & metabolism journal 35: 587–594.
17. Solli O, Stavem K, Kristiansen IS (2010) Health-related quality of life in
diabetes: The associations of complications with EQ-5D scores. Health and
Quality of Life Outcomes 8: 18.
18. Redekop WK, Rutten G, Koopmanschap MA, Wolffenbuttel BHR, Stolk RP, et
al. (2002) Health-related quality of life and treatment satisfaction in Dutch
patients with type 2 diabetes. Diabetes Care 25: 458–463.
19. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, et al. (2006)
Measurement of HRQL Using EQ-5D in Patients with Type 2 Diabetes
Mellitus in Japan. Value in Health 9: 47–53.
20. Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of
type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:
340–349.
21. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, et al. (2000) Health-related
Quality of Life in Type 2 Diabetes (T2ARDIS-2). Value in Health 3: S47–S51.
22. O’Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, et al. (2011)
Estimation of the impact of diabetes-related complications on health utilities for
patients with type 2 diabetes in Ontario, Canada. Quality of Life Research 20:
939–943.
23. Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, et al. (2009)
The economic costs of diabetes: a population-based study in Tehran, Iran.
Diabetologia 52: 1520–1527.
24. Kapur A (2007) Economic analysis of diabetes care. Indian J Med Res 125: 473–
482.
25. Sobocki P, Ekman M, A˚gren H, Krakau I, Runeson B, et al. (2007) Health-
Related Quality of Life Measured with EQ-5D in Patients Treated for
Depression in Primary Care. Value in Health 10: 153–160.
26. Quah JHM, Luo N, Ng WY, How CH, Tay EG (2011) Health-related Quality
of Life is Associated with Diabetic Complications, but not with Short-term
Diabetic Control in Primary Care. Annals Academy of Medicine Singapore 40:
276–286.
27. Peyrot M, Rubin RR (1999) Persistence of depressive symptoms in diabetic
adults. Diabetes Care 22: 448–452.
28. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, et al. (2000) Quality
of life associated with diabetes mellitus in an adult population. Journal of
Diabetes and its Complications 14: 18–24.
29. Brown DW, Balluz LS, Giles WH, Beckles GL, Moriarty DG, et al. (2004)
Diabetes mellitus and health-related quality of life among older adults. Diabetes
Research and Clinical Practice 65: 105–115.
30. Rubin RR, Peyrot M (1999) Quality of life and diabetes. Diabetes Metab Res
Rev 15: 205–218.
31. Keinanen-Kiukaanniemi S, Ohinmaa A, Pajunpaa H, Koivukangas P (1996)
Health related quality of life in diabetic patients measured by the Nottingham
Health Profile. Diabet Med 13: 382–388.
32. Hanninen J, Takala J, Keinanen-Kiukaanniemi S (1998) Quality of life in
NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract
42: 17–27.
33. Varghese RT, Salini R, Abraham P, Reeshma KK, Vijayakumar K (2007)
Determinants of the quality of life among diabetic subjects in Kerala, India.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1: 173–179.
34. Saito I, Inami F, Ikebe T, Moriwaki C, Tsubakimoto A, et al. (2006) Impact of
diabetes on health-related quality of life in a population study in Japan. Diabetes
Research and Clinical Practice 73: 51–57.
35. Lloyd A, Sawyer W, Hopkinson P (2001) Impact of Long-Term Complications
on Quality of Life in Patients with Type 2 Diabetes not Using Insulin. Value in
Health 4: 392–400.
36. Brown DW, Balluz LS, Giles WH, Beckles GL, Moriarty DG, et al. (2004)
Diabetes mellitus and health-related quality of life among older adults: Findings
from the behavioral risk factor surveillance system (BRFSS). Diabetes Research
and Clinical Practice 65: 105–115.
37. Speight J, Reaney MD, Barnard KD (2009) Not all roads lead to Rome-a review
of quality of life measurement in adults with diabetes. Diabetic Medicine 26:
315–327.
Quality of Life in Patients with Type 2 Diabetes
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e44526
